BR112023002234A2 - Anticorpos sars-cov-2 para tratamento e prevenção de covid-19 - Google Patents

Anticorpos sars-cov-2 para tratamento e prevenção de covid-19

Info

Publication number
BR112023002234A2
BR112023002234A2 BR112023002234A BR112023002234A BR112023002234A2 BR 112023002234 A2 BR112023002234 A2 BR 112023002234A2 BR 112023002234 A BR112023002234 A BR 112023002234A BR 112023002234 A BR112023002234 A BR 112023002234A BR 112023002234 A2 BR112023002234 A2 BR 112023002234A2
Authority
BR
Brazil
Prior art keywords
antibodies
covid
cov
sars
prevention
Prior art date
Application number
BR112023002234A
Other languages
English (en)
Portuguese (pt)
Inventor
Gasser Robert
Esser Mark
MCTAMNEY II Patrick
LOO Yueh-Ming
M Varkey Reena
Du Qun
Steinhardt James
Rajan Saravanan
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of BR112023002234A2 publication Critical patent/BR112023002234A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112023002234A 2020-08-10 2021-08-09 Anticorpos sars-cov-2 para tratamento e prevenção de covid-19 BR112023002234A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063063862P 2020-08-10 2020-08-10
US202063112104P 2020-11-10 2020-11-10
PCT/EP2021/072203 WO2022034044A1 (en) 2020-08-10 2021-08-09 Sars-cov-2 antibodies for treatment and prevention of covid-19

Publications (1)

Publication Number Publication Date
BR112023002234A2 true BR112023002234A2 (pt) 2023-03-07

Family

ID=77595513

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002234A BR112023002234A2 (pt) 2020-08-10 2021-08-09 Anticorpos sars-cov-2 para tratamento e prevenção de covid-19

Country Status (11)

Country Link
US (2) US20220041694A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192860A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023537078A (cg-RX-API-DMAC7.html)
KR (1) KR20230045613A (cg-RX-API-DMAC7.html)
CN (1) CN116234577A (cg-RX-API-DMAC7.html)
AU (1) AU2021325339A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002234A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190280A1 (cg-RX-API-DMAC7.html)
IL (1) IL300257A (cg-RX-API-DMAC7.html)
TW (1) TW202221025A (cg-RX-API-DMAC7.html)
WO (1) WO2022034044A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
CR20240528A (es) 2022-04-29 2025-04-04 Astrazeneca Uk Ltd Anticuerpos contra el sars-cov-2 y métodos para utilizarlos

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
CA2923247A1 (en) 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
CN102387814A (zh) 2009-01-29 2012-03-21 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
CN106604744A (zh) * 2014-09-03 2017-04-26 免疫医疗有限公司 稳定的抗IL‑4R‑α抗体配制品
WO2021195418A1 (en) * 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
PH12022553106A1 (en) * 2020-05-17 2023-11-20 Astrazeneca Uk Liimited Sars-cov-2-antibodies and methods of selecting and using the same

Also Published As

Publication number Publication date
TW202221025A (zh) 2022-06-01
IL300257A (en) 2023-03-01
AU2021325339A1 (en) 2023-04-06
US20220041694A1 (en) 2022-02-10
CN116234577A (zh) 2023-06-06
CA3190280A1 (en) 2022-02-17
EP4192860A1 (en) 2023-06-14
WO2022034044A1 (en) 2022-02-17
JP2023537078A (ja) 2023-08-30
KR20230045613A (ko) 2023-04-04
US20240092875A1 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
CL2023000705A1 (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
BR112023016580A2 (pt) Anticorpos anti-tcr delta variáveis 1
BR112022023088A2 (pt) Anticorpos contra sars-cov-2 e métodos de seleção e uso dos mesmos
DOP2024000207A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
BR112022018949A2 (pt) Anticorpos monoclonais humanos para síndrome respiratória aguda grave coronavírus 2 (sars-cov-2)
BR112022024149A2 (pt) Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno
BR112021016398A2 (pt) Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
BR112017026189A2 (pt) tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4
BR112021021713A2 (pt) Método de tratamento de câncer ou inibição do crescimento de um tumor
CY1111958T1 (el) Θεραπευτικη χρηση αντισωματων anti-csi
BRPI0506726B8 (pt) anticorpo monoclonal específico para m-csf e usos deste
BR112024000744A2 (pt) Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno
PH12022500028A1 (en) Methods for treating or preventing sars-cov-2 infections and covid -19 with anti-sars-cov-2 spike glycoprotein antibodies
MX2024009860A (es) Anticuerpos monoclonales humanos que se dirigen ampliamente a los coronavirus
BR112022024361A2 (pt) Tubulisinas e conjugados de proteína-tubulisina
ATE552852T1 (de) Zusammensetzungen und verfahren zur behandlung von virusinfektionen
BR112023016680A2 (pt) Terapias de combinação com anticorpos anti-cd38 e parp ou inibidores de receptor de adenosina
JOP20210159A1 (ar) أجسام مضادة لـ pmel17 ومترافقات منها
BR112022011350A2 (pt) Composições e métodos para tratamento e prevenção da influenza
BR112023023558A2 (pt) Anticorpos anti-tmprss6 e usos dos mesmos
MX2022001626A (es) Composiciones biofarmaceuticas y procedimientos conexos.
BR112022004302A2 (pt) Anticorpos anti-il-27 e usos dos mesmos
CL2025003288A1 (es) Anticuerpos que se unen a ox40l y métodos de uso.
BR112022014278A2 (pt) Conjugados de composto proteico-antiviral
BR112021024401A2 (pt) Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: ARQUIVADO O PEDIDO DE PATENTE, NOS TERMOS DO ARTIGO 86, DA LPI, E ARTIGO 14 DA PORTARIA 52/2023, REFERENTE AO NAO RECOLHIMENTO DA 5A RETRIBUICAO ANUAL.PARA FINS DE RESTAURACAO CONFORME ARTIGO 87, DA LPI 9.279, E ARTIGO 15, DA PORTARIA 52/2023, O DEPOSITANTE DEVERA, NO PRAZO DE 3 (TRES) MESES, PROCEDER COM:? PAGAMENTO DA GRU SERVICO 208, REFERENTE A TAXA DE RESTAURACAO DO PEDIDO.? PAGAMENTO DE 1 (UMA) GRU, SERVICO 221, REFERENTE(S) A(S) ANUIDADE(S) EM QUESTAO, NO VALOR EXTRAORDINARIO, CONFORME TABELA VIGENTE, SEGUNDO O ART. 84O 2O DA LEI NO 9.279/96. CASO NAO HAJA PAGAMENTO CONJUNTO, DENTRO DO PRAZO LEGAL, DAS RETRIBUICOES SUPRACITADAS, SERA MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, ATRA